Abeona Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
Abeona Therapeutics Inc. (Nasdaq: ABEO) announced that its CEO, João Siffert, M.D., will present at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 10:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Abeona Therapeutics Inc. (Nasdaq: ABEO) announced that its CEO, João Siffert, M.D., will present at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 10:00 a.m. ET. The live webcast can be accessed on the company's investor website, with a replay available within 24 hours for 90 days. Abeona focuses on gene and cell therapies for serious diseases, including EB-101 for epidermolysis bullosa and AAV-based therapies for Sanfilippo syndrome. The company has received multiple regulatory designations from the FDA and EMA, signaling its innovative pipeline.
Details
News Market Reaction – ABEO
The recorded move for ABEO in the trading session of this news was -1.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and CLEVELAND, May 28, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that João Siffert, M.D., Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10:00 a.m. ET.
A live webcast of the presentation will be available on the investor section of the Abeona Therapeutics website at www.abeonatherapeutics.com. The webcast replay will be available within 24 hours of the live presentation and will be accessible for 90 days.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. The Company’s clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively. The Company’s portfolio of AAV-based gene therapies also features ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively. Abeona has received numerous regulatory designations from the FDA and EMA for its pipeline candidates, including Regenerative Medicine Advanced Therapy designation for two candidates (EB-101 and ABO-102). www.abeonatherapeutics.com
Investor Contact:
Greg Gin
VP, Investor Relations
Abeona Therapeutics
+1 (646) 813-4709
ggin@abeonatherapeutics.com
Media Contact:
Scott Santiamo
Director, Corporate Communications
Abeona Therapeutics
+1 (718) 344-5843
ssantiamo@abeonatherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.